TRAINING

Pharma Integrity Signatory Training

TRAINING COURSE DETAILS

Price:

Price €3,850 pp

How Long:

4 x 0.5 half-day taught sessions + end of course validation

Dates:

Public Course 1 (February/March 2027): Thursday 4 February, Thursday 11 February, Thursday 25 February and Thursday 4 March. Validations: Thursday 11 March 2027.

Public Course 2 (September/October 2027): Thursday 16 September, Thursday 23 September, Thursday 30 September and Thursday 7 October. Validations: Thursday 14 October 2027.

This comprehensive four-week training course assesses the detailed requirements of the IPHA Code and S.I. No. 541/2007 Medicinal Products (Control of Advertising) Regulations 2007 associated with the promotion of prescription medicines in Ireland.

The market-leading course includes practical application throughout, and incorporates a robust assessment at the end. Validation certificates are provided to those who successfully complete the end-of-course assessments.

AVAILABILITY

Good to know

Please note: Places are limited to a maximum of 10 participants per course so each person has a quality learning experience. Past participants hold a variety of responsibilities within Medical Affairs, Compliance, Scientific Service, Legal and Marketing. Those interested should be aware that independent personal study between sessions is a key part of this course.

Customised in-house training programmes are available upon request.

BOOK NOW

Register your interest
or secure your place now

Book Now

TESTIMONIALS

What our clients are saying about us

What I value the most in the services provided by Pharma Integrity is constant feedback in both written and verbal manners. This is an extra benefit to work with them not just for review and approval but for continuous improvement for compliance.

Country Manager
In addition to their professional, flexible and efficient Medical Signatory services, Pharma Integrity provide an invaluable forum for educational discussions on compliance between Irish and UK affiliates. I particularly appreciate the bi-monthly update meetings that they provide to our company for the review and explanation of the rationale behind their recommendations which have upskilled all team members and in promoting compliance. The expert, evidence-based knowledge that Pharma Integrity provides has given us the confidence to expand our range of activities, including enabling us to invite Irish HCPs to educational meetings organised by other affiliates.

Medical Lead
What I value the most in the services provided by Pharma Integrity is constant feedback in both written and verbal manners. This is an extra benefit to work with them not just for review and approval but for continuous improvement for compliance.

Commercial Director
Pharma Integrity have always provided an efficient, reliable review and approval service. The team are friendly, extremely knowledgeable, approachable and always have the clients best interests in mind. The team also offer practical guidance based on their wealth of experience and I always learn something new from any interactions.

Business Unit Director
Pharma Integrity’s compliance committee meetings provide members with the opportunity to share learnings & best practices. Cross functional, peer to peer discussions foster insightful conversations which often result in solutions to code compliance nuances. These meetings create a “safe space” for industry experts to speak candidly on topical issues pertaining to medical compliance in pharma. If you work in medical affairs I would highly recommend joining!

Associate Director, Medical Affairs
In addition to their professional, flexible and efficient Medical Signatory services, Pharma Integrity provide an invaluable forum for educational discussions on compliance between Irish and UK affiliates. I particularly appreciate the bi-monthly update meetings that they provide to our company for the review and explanation of the rationale behind their recommendations which have upskilled all team members and in promoting compliance.

Compliance Lead

NEWSLETTER